Description

Insulin aspart is a recombinant human insulin analog designed for accelerated absorption and action. It differs from native insulin by replacing proline with aspartic acid at the B28 position, reducing hexamer formation and enabling rapid uptake. With an onset of action around 10–15 minutes, peak effect at ~60 minutes, and duration of 3–5 hours, it’s ideal for modeling post-meal glucose dynamics in research. Produced via genetically engineered yeast under GMP standards, this formulation has a purity of at least 95%. It is intended strictly for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Insulin aspart binds to insulin receptors on target cells, promoting glucose uptake and inhibiting hepatic glucose production, mimicking endogenous insulin action with rapid onset and short duration. It is especially useful for investigating postprandial glucose metabolism, insulin pharmacodynamics, and drug-receptor interaction modeling.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Handle according to institutional safety protocols.